GlaxoSmithKline PLC has received FDA approval to market a new once-daily formulation of Requip XL, a treatment for Parkinson's disease and restless legs syndrome. The new version will "provide smoother blood levels without the peaks and troughs that multiple daily doses typically deliver," a neurology expert said in the company's statement.

Full Story:

Related Summaries